Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

NCT00152009 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

345

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: SPD503 (Guanfacine hydrochloride) (2 mg)
DRUG: SPD503 (3 mg)
DRUG: SPD503 (4 mg)
DRUG: Placebo

Sponsor

Shire